Literature DB >> 6838068

Clindamycin compared with penicillin for the treatment of anaerobic lung abscess.

M E Levison, C T Mangura, B Lorber, E Abrutyn, E L Pesanti, R S Levy, R R MacGregor, A R Schwartz.   

Abstract

The clinical efficacy of clindamycin was compared with that of penicillin in a randomized study of the treatment of community-acquired putrid lung abscess. After starting therapy, patients treated with clindamycin had a shorter febrile period and fewer days of fetid sputum than patients treated with penicillin (mean 4.4 versus 7.6 days and 4.2 versus 8.0 days, respectively, p less than 0.05). Four of 20 patients treated with penicillin had clinically significant pulmonary or pleural extension of their infection within 10 days after starting therapy; this was not found in any of 19 patients treated with clindamycin (p less than 0.05). Penicillin treatment failed in two additional patients after 20 days of therapy. Within 1 month after treatment, 1 of 4 patients given penicillin for 3 weeks had relapse, but none of the 13 patients given clindamycin for 3 or 6 weeks, and none of the 5 patients given penicillin for 6 weeks had relapse. Overall, only 8 of 15 patients treated with penicillin who could be followed to the end of the study were cured, whereas all 13 patients treated with clindamycin who could be followed were cured (p less than 0.01). These results suggest that penicillin may not be optimal therapy for anaerobic lung abscess.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838068     DOI: 10.7326/0003-4819-98-4-466

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  18 in total

1.  Anaerobic Infections of the Lung.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 3.  Lemierre's syndrome: more than a historical curiosa.

Authors:  T Riordan; M Wilson
Journal:  Postgrad Med J       Date:  2004-06       Impact factor: 2.401

4.  Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazole.

Authors:  J A Bosso; R A Prince
Journal:  Tex Heart Inst J       Date:  1990

Review 5.  Post-resection complications: abscesses, empyemas, bronchopleural fistulas.

Authors:  Matthew Egyud; Kei Suzuki
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 6.  Current antimicrobial therapy of anaerobic infections.

Authors:  C V Sanders; K E Aldridge
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

7.  Chest diseases: lung abscess.

Authors:  R C Arai; G A Lillington
Journal:  West J Med       Date:  1986-03

8.  Lung abscess in an immunocompromised patient: clinical presentation and management challenges.

Authors:  Isabel M Eira; Renata Carvalho; Diana Vale Carvalho; Cristina Ângela
Journal:  BMJ Case Rep       Date:  2019-07-16

9.  Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections.

Authors:  N Fernández-Sabé; J Carratalà; J Dorca; B Rosón; F Tubau; F Manresa; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

Review 10.  The role of beta-lactamase-producing-bacteria in mixed infections.

Authors:  Itzhak Brook
Journal:  BMC Infect Dis       Date:  2009-12-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.